Abstract: With the deepening of the lung cancer molecular biology research, small molecular targets antitumor drugs make breakthrough progress, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) is one of the most attention drug. A series studies show that EGFRTKI can enhance the antitumor activity of ionizing radiation. Therefore, EGFRTKI combined with radiotherapy alone for poorrisk patients appears survival benefit, but can′t ignore the lung toxicity. However, there is a big controversy that EGFRTKI combined with chemoradiotherapy for locally advanced NSCLC.

Key words: Carcinoma, nonsmallcell lung, Radiotherapy, Epidermal growth factor receptor tyrosine kinase inhibitor